Needham & Company LLC Issues Positive Forecast for TransMedics Group (NASDAQ:TMDX) Stock Price

TransMedics Group (NASDAQ:TMDX) had its target price boosted by Needham & Company LLC from $106.00 to $110.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research firms also recently weighed in on TMDX. Piper Sandler reiterated an “overweight” rating and set a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Barclays started coverage on TransMedics Group in a research report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price target for the company. TD Cowen reaffirmed a “buy” rating and issued a $120.00 price objective on shares of TransMedics Group in a research note on Tuesday, September 8th. Weiss Ratings raised TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Finally, Canaccord Genuity Group boosted their price objective on TransMedics Group from $95.00 to $120.00 and gave the company a “buy” rating in a research note on Friday. Five analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Hold” and an average price target of $118.60.

TransMedics Group Stock Performance

Shares of TMDX traded up $19.26 on Friday, reaching $88.24. The company’s stock had a trading volume of 3,950,703 shares, compared to its average volume of 860,048. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07. The stock has a market capitalization of $3.05 billion, a P/E ratio of 23.91, a PEG ratio of 0.92 and a beta of 2.14. The stock’s 50 day simple moving average is $79.61 and its two-hundred day simple moving average is $93.17. TransMedics Group has a 12-month low of $60.10 and a 12-month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Thursday, November 5th. The company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.30 by $0.21. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The business had revenue of $203.01 million during the quarter, compared to analysts’ expectations of $178.06 million. During the same period in the prior year, the company earned $0.66 earnings per share. The firm’s revenue was up 41.1% on a year-over-year basis. Research analysts forecast that TransMedics Group will post 1.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director David Weill bought 1,336 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was bought at an average price of $81.63 per share, with a total value of $109,057.68. Following the acquisition, the director owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. This represents a 8.87% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several large investors have recently made changes to their positions in TMDX. Headlands Technologies LLC bought a new stake in TransMedics Group during the 2nd quarter valued at approximately $1,634,000. The Manufacturers Life Insurance Company bought a new position in TransMedics Group in the 2nd quarter worth approximately $1,140,000. Candriam S.C.A. boosted its stake in TransMedics Group by 45.4% in the 1st quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock worth $15,783,000 after purchasing an additional 49,580 shares during the period. FirstWave Capital Management LLC grew its holdings in TransMedics Group by 53.9% during the 2nd quarter. FirstWave Capital Management LLC now owns 191,240 shares of the company’s stock valued at $12,702,000 after buying an additional 66,972 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in TransMedics Group by 6.1% during the 2nd quarter. Wellington Management Group LLP now owns 515,973 shares of the company’s stock valued at $34,271,000 after buying an additional 29,500 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Key TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Third-quarter revenue was $203.0 million, up 41.1% year over year and above the roughly $178 million consensus. Adjusted earnings of $0.51 per share also beat estimates of about $0.30, supporting the growth outlook. TransMedics Q3 2026 results
• Positive Sentiment: TransMedics raised its 2026 revenue guidance to $764 million–$774 million, a signal of confidence in continued business growth. Needham also raised its price target from $106 to $110 and reiterated a Buy rating. Revenue guidance and catalyst update Needham recommendations
• Neutral Sentiment: Unusual options activity followed the earnings report, indicating heightened trading interest but not a clear directional signal. Unusual options activity report
• Negative Sentiment: ENHANCE Part B and DENOVO catalysts have shifted to early 2027, delaying potential near-term developments. EPS was also below the year-ago quarter’s $0.66, despite beating analyst estimates. Catalyst timing update

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.